Vladimir Coric, Christopher H van Dyck, Stephen Salloway, Niels Andreasen, Mark Brody, Ralph W Richter, Hilkka Soininen, Stephen Thein, Thomas Shiovitz, Gary Pilcher, Susan Colby, Linda Rollin, Randy Dockens, Chahin Pachai, Erik Portelius, Ulf Andreasson, Kaj Blennow, Holly Soares, Charles Albright, Howard H Feldman, Robert M Berman
{"title":"γ-分泌酶抑制剂avagacestat在轻至中度阿尔茨海默病的2期研究中的安全性和耐受性","authors":"Vladimir Coric, Christopher H van Dyck, Stephen Salloway, Niels Andreasen, Mark Brody, Ralph W Richter, Hilkka Soininen, Stephen Thein, Thomas Shiovitz, Gary Pilcher, Susan Colby, Linda Rollin, Randy Dockens, Chahin Pachai, Erik Portelius, Ulf Andreasson, Kaj Blennow, Holly Soares, Charles Albright, Howard H Feldman, Robert M Berman","doi":"10.1001/archneurol.2012.2194","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).</p><p><strong>Design: </strong>Randomized, double-blind, placebo-controlled,24-week phase 2 study.</p><p><strong>Setting: </strong>Global, multicenter trial.</p><p><strong>Patients: </strong>A total of 209 outpatients with mild to moderate AD were randomized into the double-blind treatment phase. The median age of the patients was 75 years,58.9% were APOE ε4 carriers, and baseline measures of disease severity were similar among groups.</p><p><strong>Intervention: </strong>Avagacestat, 25, 50, 100, or 125 mg daily,or placebo administered orally daily.</p><p><strong>Main outcome measures: </strong>Safety and tolerability of avagacestat.</p><p><strong>Results: </strong>Discontinuation rates for the 25-mg and 50-mg doses of avagacestat were comparable with placebo but were higher in the 100-mg and 125-mg dose groups.Trends for worsening cognition, as measured by change from baseline Alzheimer Disease Assessment Scale cognitive subscale score, were observed in the 100-mg and125-mg dose groups. Treatment-emergent serious adverse events were similar across placebo and treatment groups. The most common reason for discontinuation was adverse events, predominantly gastrointestinal anddermatologic. Other adverse events occurring more frequentlyin patients undergoing treatment included reversibleglycosuria (without associated serum glucose changes), nonmelanoma skin cancer, and asymptomaticmagnetic resonance imaging findings. Exploratory cerebrospinal fluid amyloid isoforms and tau biomarker analysis demonstrated dose-dependent but not statistically significant reductions in a small subset of patients.</p><p><strong>Conclusions: </strong>Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates. The 100-mg and 125-mg dose arms were poorly tolerated with trends for cognitive worsening. Exploratory cerebrospinal fluid biomarker substudies provide preliminary support for -secretase target engagement,but additional studies are warranted to better characterize pharmacodynamic effects at the 25- and 50-mg doses.This study establishes an acceptable safety and tolerability dose range for future avagacestat studies in AD.</p><p><strong>Trial registration: </strong>clinicaltrials.gov Identifier: NCT00810147</p>","PeriodicalId":8321,"journal":{"name":"Archives of neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archneurol.2012.2194","citationCount":"312","resultStr":"{\"title\":\"Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.\",\"authors\":\"Vladimir Coric, Christopher H van Dyck, Stephen Salloway, Niels Andreasen, Mark Brody, Ralph W Richter, Hilkka Soininen, Stephen Thein, Thomas Shiovitz, Gary Pilcher, Susan Colby, Linda Rollin, Randy Dockens, Chahin Pachai, Erik Portelius, Ulf Andreasson, Kaj Blennow, Holly Soares, Charles Albright, Howard H Feldman, Robert M Berman\",\"doi\":\"10.1001/archneurol.2012.2194\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).</p><p><strong>Design: </strong>Randomized, double-blind, placebo-controlled,24-week phase 2 study.</p><p><strong>Setting: </strong>Global, multicenter trial.</p><p><strong>Patients: </strong>A total of 209 outpatients with mild to moderate AD were randomized into the double-blind treatment phase. The median age of the patients was 75 years,58.9% were APOE ε4 carriers, and baseline measures of disease severity were similar among groups.</p><p><strong>Intervention: </strong>Avagacestat, 25, 50, 100, or 125 mg daily,or placebo administered orally daily.</p><p><strong>Main outcome measures: </strong>Safety and tolerability of avagacestat.</p><p><strong>Results: </strong>Discontinuation rates for the 25-mg and 50-mg doses of avagacestat were comparable with placebo but were higher in the 100-mg and 125-mg dose groups.Trends for worsening cognition, as measured by change from baseline Alzheimer Disease Assessment Scale cognitive subscale score, were observed in the 100-mg and125-mg dose groups. Treatment-emergent serious adverse events were similar across placebo and treatment groups. The most common reason for discontinuation was adverse events, predominantly gastrointestinal anddermatologic. Other adverse events occurring more frequentlyin patients undergoing treatment included reversibleglycosuria (without associated serum glucose changes), nonmelanoma skin cancer, and asymptomaticmagnetic resonance imaging findings. Exploratory cerebrospinal fluid amyloid isoforms and tau biomarker analysis demonstrated dose-dependent but not statistically significant reductions in a small subset of patients.</p><p><strong>Conclusions: </strong>Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates. The 100-mg and 125-mg dose arms were poorly tolerated with trends for cognitive worsening. Exploratory cerebrospinal fluid biomarker substudies provide preliminary support for -secretase target engagement,but additional studies are warranted to better characterize pharmacodynamic effects at the 25- and 50-mg doses.This study establishes an acceptable safety and tolerability dose range for future avagacestat studies in AD.</p><p><strong>Trial registration: </strong>clinicaltrials.gov Identifier: NCT00810147</p>\",\"PeriodicalId\":8321,\"journal\":{\"name\":\"Archives of neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1001/archneurol.2012.2194\",\"citationCount\":\"312\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/archneurol.2012.2194\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/archneurol.2012.2194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Objective: To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).
Patients: A total of 209 outpatients with mild to moderate AD were randomized into the double-blind treatment phase. The median age of the patients was 75 years,58.9% were APOE ε4 carriers, and baseline measures of disease severity were similar among groups.
Main outcome measures: Safety and tolerability of avagacestat.
Results: Discontinuation rates for the 25-mg and 50-mg doses of avagacestat were comparable with placebo but were higher in the 100-mg and 125-mg dose groups.Trends for worsening cognition, as measured by change from baseline Alzheimer Disease Assessment Scale cognitive subscale score, were observed in the 100-mg and125-mg dose groups. Treatment-emergent serious adverse events were similar across placebo and treatment groups. The most common reason for discontinuation was adverse events, predominantly gastrointestinal anddermatologic. Other adverse events occurring more frequentlyin patients undergoing treatment included reversibleglycosuria (without associated serum glucose changes), nonmelanoma skin cancer, and asymptomaticmagnetic resonance imaging findings. Exploratory cerebrospinal fluid amyloid isoforms and tau biomarker analysis demonstrated dose-dependent but not statistically significant reductions in a small subset of patients.
Conclusions: Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates. The 100-mg and 125-mg dose arms were poorly tolerated with trends for cognitive worsening. Exploratory cerebrospinal fluid biomarker substudies provide preliminary support for -secretase target engagement,but additional studies are warranted to better characterize pharmacodynamic effects at the 25- and 50-mg doses.This study establishes an acceptable safety and tolerability dose range for future avagacestat studies in AD.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
